In clinical trials in type 2 diabetes or chronic kidney disease, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced the risk of hospitalizations for heart failure.8–14 However, these trials did not evaluate the effect of these drugs on the broad spectrum of both inpatient and outpatient heart failure events. This evidence concerns the gene SLC5A2 and chronic kidney disease.